CompletedNCT01485640
Long-Term Lurasidone Safety After Treatment for Schizophrenia or Bipolarity
About this title
Read the official source — NCT01485640Medication studyMultiple countries
Understand this study
- Listed locations
- Kelowna and 45 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 162
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, Canada, Colombia, ...
- Age range
- Not clearly listed
- Official registry ID
- NCT01485640
- Official title
Show the full official title
A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedKelowna, Canada · Barranquilla, Colombia · Bello, Colombia
36 more locations
- Bogotá, Colombia
- Brno-mesto, Czechia
- Olomouc, Czechia
- Prague, Czechia
- Orvault, France
- Toulun, France
- Visakhapatnam, India
- Vijayawada, India
- Ahmedabad, India
- Jūnāgadh, India
- Vadodara, India
- Chhatrapati Sambhajinagar, India
- Jaipur, India
- Kanpur, India
- Kaunas, Lithuania
- Vilnius, Lithuania
- Cluj-Napoca, Romania
- Craiova, Romania
- Lipetsk, Russia
- Saint Petersburg, Russia
- Belgrade, Serbia
- Niš, Serbia
- Bratislava, Slovakia
- Rimavská Sobota, Slovakia
- Svidník, Slovakia
- Trenčín, Slovakia
- Pretoria, South Africa
- Tygervalley, South Africa
- Kherson, Ukraine
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Khardov, Ukraine
- Simferopol, Ukraine
- Vinnitsia, Ukraine
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Lurasidone.
Want to explore more studies?
Explore studiesRelated studies
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolarity type I
A randomized, parallel group, multiple dose, 6 week study to evaluate safety, tolerability, and pharmacokinetics of asenapine in elderly subjects with psychosis.